Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
6.45
-0.16 (-2.35%)
Mar 31, 2025, 10:51 AM EDT - Market open
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Phathom Pharmaceuticals stock have an average target of 23, with a low estimate of 12 and a high estimate of 28. The average target predicts an increase of 256.87% from the current stock price of 6.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $18 → $12 | Hold | Maintains | $18 → $12 | +86.19% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +334.45% | Mar 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +334.45% | Mar 6, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +334.45% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +334.45% | Dec 12, 2024 |
Financial Forecast
Revenue This Year
168.13M
from 55.25M
Increased by 204.30%
Revenue Next Year
381.62M
from 168.13M
Increased by 126.98%
EPS This Year
-4.50
from -5.29
EPS Next Year
-2.19
from -4.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 207.7M | 515.0M | 871.6M | ||
| Avg | 168.1M | 381.6M | 607.3M | ||
| Low | 134.5M | 268.4M | 481.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 275.9% | 206.3% | 128.4% | ||
| Avg | 204.3% | 127.0% | 59.1% | ||
| Low | 143.5% | 59.6% | 26.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.62 | -0.35 | -0.01 | ||
| Avg | -4.50 | -2.19 | -0.34 | ||
| Low | -5.94 | -2.85 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.